Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EV-PRIME: Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy as a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer

NCT06470282 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT06470282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EV-PRIME: Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy as a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer
Lead sponsor
University of California, San Francisco
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 31, 2025
Completion date
January 31, 2028
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, muscle-invasive bladder carcinoma, stage ii bladder cancer ajcc v8, stage iiia bladder cancer ajcc v8